Hearing Loss, High-Frequency
                             
                            
                            
                                
                            
                            
                                
                            
                            
                            
                                
                                    
                                            
	"Hearing Loss, High-Frequency" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, 
	MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, 
	which enables searching at various levels of specificity.
	
	
		
			
			
				Hearing loss in frequencies above 1000 hertz.
    
			
			
				
				
					
						| Descriptor ID | D006316 | 
					
						| MeSH Number(s) | C09.218.458.341.812 C10.597.751.418.341.812 C23.888.592.763.393.341.812 | 
					
						| Concept/Terms |  | 
					
				
			 
			
				Below are MeSH descriptors whose meaning is more general than "Hearing Loss, High-Frequency".
				
			 
			
			
				Below are MeSH descriptors whose meaning is more specific than "Hearing Loss, High-Frequency".
				
			 
		 
	 
 
                                        
                                            
	
	
		
			
			
					
				This graph shows the total number of publications written about "Hearing Loss, High-Frequency" by people in this website by year, and whether "Hearing Loss, High-Frequency" was a major or minor topic of these publications. 
				
					 
                    To see the data from this visualization as text, 
click here. 
                
		            | Year | Major Topic | Minor Topic | Total | 
|---|
| 2017 | 0 | 1 | 1 | 
                    To return to the timeline, 
click here.
                 
			 	
			
			
			
			
				Below are the most recent publications written about "Hearing Loss, High-Frequency" by people in Profiles.
						
					
								- 
								Intrathecal 2-hydroxypropyl-?-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial. Lancet. 2017 Oct 14; 390(10104):1758-1768.